Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 13.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,376 shares of the biopharmaceutical company's stock after acquiring an additional 24,620 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.22% of Ultragenyx Pharmaceutical worth $8,514,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Invesco Ltd. lifted its position in Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after acquiring an additional 25,487 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Ultragenyx Pharmaceutical by 5.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after buying an additional 81,667 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock worth $63,105,000 after purchasing an additional 750,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its stake in Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock valued at $60,570,000 after buying an additional 269,733 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on RARE shares. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. William Blair started coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Finally, Piper Sandler lowered their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $88.77.

Insider Activity

In other news, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 2,547 shares of company stock worth $101,015. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Up 0.6%

NASDAQ:RARE traded up $0.21 on Wednesday, reaching $36.61. 759,203 shares of the company's stock were exchanged, compared to its average volume of 840,220. The business has a fifty day moving average of $35.50 and a 200-day moving average of $40.50. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -5.77 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million during the quarter, compared to analysts' expectations of $145.98 million. During the same quarter in the prior year, the company earned ($2.03) earnings per share. The firm's revenue was up 28.0% compared to the same quarter last year. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.